🚀 VC round data is live in beta, check it out!
Curatis Holding Valuation Multiples
Discover revenue and EBITDA valuation multiples for Curatis Holding and similar public comparables like Heidelberg Pharma, Kotra Industries, Dimerix, Cardiol Therapeutics and more.
Curatis Holding Overview
About Curatis Holding
Curatis Holding AG is a specialty pharmaceutical company based in Switzerland. It focus on the acquisition, development and commercialisation of medicines for the prevention, diagnosis and treatment of rare and specialty care diseases. Curatis is engaged in two business areas: Distribution business for orphan disease and specialty care medicines and Development business for orphan and specialty care disease medicines. Its product include Aggrastat (Tirofiban), AmbiFul (Fulvestrant), Brinavess (Vernakalant), Coldistop, Cuprior (Trientin), Cyanokit (Hydroxocobalamin), etc.
Founded
1997
HQ
Employees
7
Website
Sectors
Financials (FY)
EV
$150M
Curatis Holding Financials
Curatis Holding reported last fiscal year revenue of $14M and negative EBITDA of ($1M).
In the same fiscal year, Curatis Holding generated $4M in gross profit, ($1M) in EBITDA losses, and had net loss of ($2M).
Revenue (LTM)
Curatis Holding P&L
In the most recent fiscal year, Curatis Holding reported revenue of $14M and EBITDA of ($1M).
Curatis Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $14M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $4M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 26% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($1M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (10%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (14%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($2M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (13%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Curatis Holding Stock Performance
Curatis Holding has current market cap of $154M, and enterprise value of $150M.
Market Cap Evolution
Curatis Holding's stock price is $29.82.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $150M | $154M | -0.1% | XXX | XXX | XXX | $-0.35 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCuratis Holding Valuation Multiples
Curatis Holding trades at 11.0x EV/Revenue multiple, and (105.3x) EV/EBITDA.
EV / Revenue (LTM)
Curatis Holding Financial Valuation Multiples
As of April 11, 2026, Curatis Holding has market cap of $154M and EV of $150M.
Equity research analysts estimate Curatis Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Curatis Holding has a P/E ratio of (85.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $154M | XXX | $154M | XXX | XXX | XXX |
| EV (current) | $150M | XXX | $150M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 11.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (105.3x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (76.8x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 41.7x | XXX | XXX | XXX |
| P/E | — | XXX | (85.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (46.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Curatis Holding Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Curatis Holding Margins & Growth Rates
Curatis Holding's revenue in the last fiscal year grew by 57%.
Curatis Holding's revenue per employee in the last FY averaged $1.9M, while opex per employee averaged $0.8M for the same period.
Curatis Holding Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 57% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (10%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (74%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.9M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 12% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 41% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Curatis Holding Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Heidelberg Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Kotra Industries | XXX | XXX | XXX | XXX | XXX | XXX |
| Dimerix | XXX | XXX | XXX | XXX | XXX | XXX |
| Cardiol Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Starpharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Curatis Holding M&A Activity
Curatis Holding acquired XXX companies to date.
Last acquisition by Curatis Holding was on XXXXXXXX, XXXXX. Curatis Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Curatis Holding
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCuratis Holding Investment Activity
Curatis Holding invested in XXX companies to date.
Curatis Holding made its latest investment on XXXXXXXX, XXXXX. Curatis Holding invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Curatis Holding
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Curatis Holding
| When was Curatis Holding founded? | Curatis Holding was founded in 1997. |
| Where is Curatis Holding headquartered? | Curatis Holding is headquartered in Switzerland. |
| How many employees does Curatis Holding have? | As of today, Curatis Holding has over 7 employees. |
| Is Curatis Holding publicly listed? | Yes, Curatis Holding is a public company listed on SIX Swiss Exchange. |
| What is the stock symbol of Curatis Holding? | Curatis Holding trades under CURN ticker. |
| When did Curatis Holding go public? | Curatis Holding went public in 2022. |
| Who are competitors of Curatis Holding? | Curatis Holding main competitors are Heidelberg Pharma, Kotra Industries, Dimerix, Cardiol Therapeutics. |
| What is the current market cap of Curatis Holding? | Curatis Holding's current market cap is $154M. |
| What is the current revenue of Curatis Holding? | Curatis Holding's last fiscal year revenue is $14M. |
| What is the current EV/Revenue multiple of Curatis Holding? | Current revenue multiple of Curatis Holding is 11.0x. |
| Is Curatis Holding profitable? | No, Curatis Holding is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.